Expert Opinion on Biological Therapy

Article	Citations
Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’?	83
Mesothelin-targeted CAR-T cell therapy for solid tumors	72
Core decompression isolated or combined with bone marrow-derived cell therapies for femoral head osteonecrosis	54
An overview of process development for antibody-drug conjugates produced by chemical conjugation technology	48
Therapeutic monoclonal antibodies for COVID-19 management: an update	45
New frontiers in personalized medicine in psoriasis	44
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma	43
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study	40
Targeting the complement system in neuromyelitis optica spectrum disorder	40
Treating psoriasis in the elderly: biologics and small molecules	34
Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions	33
A comprehensive review on sarilumab in COVID-19	32
Anti-CD20 treatment for B-cell malignancies: current status and future directions	31
Hemophilia A gene therapy: current and next-generation approaches	30
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan	29
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics	29
What makes a good antibody–drug conjugate?	29
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis	28
The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database	27
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy	27
Immune checkpoint inhibition in COVID-19: risks and benefits	27
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?	26
Margetuximab for the treatment of HER2-positive metastatic breast cancer	26
Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy – what are we doing; where are we going?	25
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19	25

Anticalin® proteins: from bench to bedside	25
Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus	24
The effect of platelet-rich plasma-fibrin glue dressing in combination with oral vitamin E and C for treatment of non-healing diabetic foot ulcers: a randomized, double-blind, parallel-group, clinical	24
Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders	24
A health economic guide to market access of biosimilars	24
Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy	24
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma	24
B7-H3 targeted antibody-based immunotherapy of malignant diseases	23
Isatuximab for the treatment of relapsed/refractory multiple myeloma	23
Rotavirus vaccines: progress and new developments	23
RNA therapeutics for retinal diseases	21
The evolution of bispecific antibodies	21
Therapeutic potential of biologics in prurigo nodularis	20
Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma	20
AIRMESS – Academy of International Regenerative Medicine & Surgery Societies: recommendations in the use of platelet-rich plasma (PRP), autologous stem cell-based therapy (ASC-BT) in androgenetic	20
Prostate cancer immunotherapy	20
Enfortumab vedotin – next game-changer in urothelial cancer	20
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy	20
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy	19
HIV-1 cure strategies: why CRISPR?	18
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond	18
Onasemnogene abeparvovec for the treatment of spinal muscular atrophy	18
Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis	18
Ranibizumab for the treatment of diabetic retinopathy	16
Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer	16
Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD	16
An inflammatory triangle in Sarcoidosis: PPAR-γ, immune microenvironment, and inflammation	15
Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice	15
Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?	15
Immune checkpoint inhibitors for the treatment of melanoma	14
Survivin as a biological biomarker for diagnosis and therapy	14
Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome	14
Targeting glyco-immune checkpoints for cancer therapy	14
Injectable and adhesive hydrogels for dealing with wounds	14
Conventional type 1 dendritic cells (cDC1) as cancer therapeutics: challenges and opportunities	13
The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?	13
The emerging role of dupilumab in dermatological indications	13
Biologics in food allergy: up-to-date	13
CRISPR/Cas9 gene editing therapies for cystic fibrosis	13
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phas	13
A Randomized Controlled Ixekizumab Vs Secukinumab Trial to Study the Impact on Sexual Activity in Adult Patients with Genital Psoriasis	13
Potential applications of mesenchymal stem cells and their derived exosomes in regenerative medicine	12
Self-administration of omalizumab: why not? A literature review and expert opinion	12
A review of imlifidase in solid organ transplantation	12
Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy	12
Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma	12
Mechanism of Action of Mesenchymal Stem Cells (MSCs): impact of delivery method	12
Next steps for the optimization of exon therapy for Duchenne muscular dystrophy	12
Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis	12
Luspatercept for β-thalassemia: beyond red blood cell transfusions	12

Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations	12
Gene Therapy for High Grade Glioma: The Clinical Experience	11
Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience	11
Anti-IL 23 biologics for the treatment of plaque psoriasis	11
Bio-nano scale modifications of melittin for improving therapeutic efficacy	11
Belimumab: a step forward in the treatment of systemic lupus erythematosus	11
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives	11
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy	11
Bispecific antibodies for the treatment of breast cancer	11
Immunomodulatory extracellular vesicles: an alternative to cell therapy for COVID-19	10
Envafolimab – first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors	10
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study	10
Role of extracellular vesicles in severe pneumonia and sepsis	10
Oncolytic virus therapy for malignant gliomas: entering the new era	10
Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk	10
Emerging treatment landscape of non-muscle invasive bladder cancer	10
Classification and coding systems for platelet-rich plasma (PRP): a peek into the history	9
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents	9
Sargramostim in acute radiation syndrome	9
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	9
Gene therapy for alpha-1 antitrypsin deficiency: an update	9
Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer	9
IL-23 inhibition for the treatment of psoriatic arthritis	9
Platelet-rich plasma therapy ensures pain reduction in the management of lateral epicondylitis – a PRISMA-compliant network meta-analysis of randomized controlled trials	9
Harmonizing PD-L1 testing in metastatic triple negative breast cancer	9
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors	9
Evaluation of canine bone marrow-derived mesenchymal stem cells for experimental full-thickness cutaneous wounds in a diabetic rat model	9
Alternative therapeutic strategy for existing aortic aneurysms using mesenchymal stem cell–derived exosomes	9
Paradoxical reactions to biologicals for psoriasis	9
Bispecific CAR T-cells for B-cell Malignancies	9
Total pancreatectomy with intraportal islet autotransplantation for pancreatic malignancies: a literature overview	9
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry	9
The manufacturing considerations of bispecific antibodies	9
Nivolumab for the treatment of esophageal cancer	9
Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus	9
Biological and genetic therapies for the treatment of Duchenne muscular dystrophy	8
Current developments in gene therapy for epidermolysis bullosa	8
Tocilizumab for the treatment of COVID-19	8
Biological agents targeting interleukin-13 for atopic dermatitis	8
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks	8
IBD goes home: from telemedicine to self-administered advanced therapies	8
Current and Future Options of Haemophilia A Treatments	8
Cell-based therapy in soft tissue sports injuries of the knee: a systematic review	8
Cell therapy for cytomegalovirus infection	8
Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation	8
A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence	8
Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing	8
Biosimilars: A futuristic fast-to-market advice to developers	8
The Role of Anti-IL-1 Treatment in MIS-C Patients	8
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease	8
How can clinical safety and efficacy concerns in stem cell therapy for spinal cord injury be overcome?	8
Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi TM ): a multidisciplinary perspective	8
Current status of developing tissue engineering vascular technologies	8
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study	8
Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques	8
Biologic treatment of psoriasis in oncologic patients	8
The global landscape on interchangeability of biosimilars	8
Emerging therapies for human hearing loss	8
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy	7
Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis	7
Rilonacept for the treatment of recurrent pericarditis	7
Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis	7
Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men	7
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	7
Applications of mesenchymal stem cells in ocular surface diseases: sources and routes of delivery	7
Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia	7
Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin	7
The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission	7
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)	7
Belimumab for the treatment of pediatric patients with lupus nephritis	7
Near infrared photoimmunotherapy targeting the cutaneous lymphocyte antigen for mycosis fungoides	7
Original antigen sin and COVID-19: implications for seasonal vaccination	7
Belantamab mafodotin in multiple myeloma	7
Trypsinogen and chymotrypsinogen: potent anti-tumor agents	7
Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer	7
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol	7
CAR-NK cells: a promising cellular immunotherapy in lymphoma	7
The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review	6
Current and emerging biologics for the treatment of pediatric atopic dermatitis	6
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors	6

Eptinezumab for the treatment of migraine	6
Bispecific antibodies for immune cell retargeting against cancer	6
Advances in biological and targeted therapies for systemic sclerosis	6
Rituximab in Myasthenia Gravis - Where do we stand?	6
KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine	6
Emerging role of monoclonal antibodies in the treatment of IgA nephropathy	6
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis	6
Biologics for dengue prevention: up-to-date	6
IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?	6
Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group	6
Advanced clinical imaging for the evaluation of stem cell based therapies	6
Regenerative replacement of neural cells for treatment of spinal cord injury	6
Flow cytometry and receptor occupancy in immune-oncology	6
Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis	6
Lisocabtagene Maraleucel for the treatment of B-cell lymphoma	6
Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces	6
Pathogenesis-oriented therapy of psoriasis using biologics	6
Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer	6
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	6
Biological therapies for myasthenia gravis	6
Classification and coding of platelet-rich plasma derived from New Zealand white rabbits for tissue engineering and regenerative medicine applications	6
Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe	6
Genetic modification and preconditioning strategies to enhance functionality of mesenchymal stromal cells: a clinical perspective	6
Biological medication in atopic dermatitis	5
Dynamics of biosimilar uptake in emerging markets	5
Biological treatment for erythrodermic psoriasis	5
Treatment of fibrous dysplasia: focus on denosumab	5
Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?	5
Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-α anta	5
Biologic therapies for chronic obstructive pulmonary disease	5
Utility of tocilizumab in autoimmune eye diseases	5
Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness	5
Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma	5
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz	5
Where do we stand with radioimmunotherapy for acute myeloid leukemia?	5
Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study	5
The evolving therapeutic landscape of diabetic retinopathy	5
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms	5
Dental stem cells for tooth regeneration: how far have we come and where next?	5
Where could gammadelta T cells take us in the treatment of cancer?	5
The role of microbiota in allogeneic hematopoietic stem cell transplantation	5
Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies	5
Epitope characterization of anti-drug antibodies—a tool for discovery and health: an overview of the necessity of early epitope characterization to avoid anti-drug antibodies and promote patient healt	5
Monoclonal antibodies for treatment of cold agglutinin disease	5
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	5
Treatment of migraine with monoclonal antibodies	5
Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease	5
Anti -TNFα agents in preventing the postoperative recurrence of Crohn’s disease: Do they still play a role in the biological era?	5
Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment	5
Isatuximab in multiple myeloma	4
Antibody based therapeutics for autoimmune hemolytic anemia	4
Recent advances in delivering RNA-based therapeutics to mitochondria	4
Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?	4
Up-to-date role of aflibercept in the treatment of colorectal cancer	4
Need for a risk-based control strategy for managing glycosylation profile for biosimilar products	4
What’s new and what’s next for gene therapy in Pompe disease?	4
Development of multi-epitope vaccine constructs for non-small cell lung cancer (NSCLC) against USA human leukocyte antigen background: an immunoinformatic approach toward future vaccine designing	4
Elotuzumab in multiple myeloma	4
Merits of the ‘good’ viruses: the potential of virus-based therapeutics	4
Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics	4
Optimizing the use of vilobelimab for the treatment of COVID-19	4
Enhancing gene therapy regulatory interactions	4
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year	4
More failure with solanezumab – this time in preclinical Alzheimer’s disease	4
Platelet-rich therapies as an emerging platform for regenerative medicine	4
Recent advances in stem cell therapy for erectile dysfunction: a narrative review	4
Analytical similarity assessment of MYL-1402O to reference Bevacizumab	4
Adipose-derived stromal/stem cells and extracellular vesicles for cancer therapy	4
Blood-based prognostic biomarkers in Crohn’s Disease patients on biologics: a promising tool to predict endoscopic outcomes	4
Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review	4
Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseases	4
Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development	4
Cardiometabolic comorbidity in the selection of treatment in spondyloarthritis: one step closer to truly personalized medicine?	4
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chron	4
Genetic screening in new onset inflammatory bowel disease during anti-interleukin 17 therapy: unmet needs and call for action	4
An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma	4
Perceptions of airway gene therapy for cystic fibrosis	4
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection	4
Clinical development of an anti-GPC-1 antibody for the treatment of cancer	3
Association between cumulative rATG induction doses and kidney graft outcomes and adverse effects in kidney transplant patients: a systematic review and meta-analysis	3
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	3
Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to acceler	3
The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries	3
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	3
Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?	3
Experts’ review: the emerging roles of romiplostim in immune thrombocytopenia (ITP)	3
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study	3
Antibody therapeutics for epithelial ovarian cancer	3
Biologic insights from single-cell studies of psoriasis and psoriatic arthritis	3
Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa	3
The landscape of biosimilars in Saudi Arabia: preparing for the next decade	3
Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity	3
Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer	3
Biological therapy in elderly patients with acute myeloid leukemia	3
Bispecific antibodies for the treatment of hemophilia A	3